Search Results

Displaying Results 51-75 of 199 "'DIS'"

Jun 16, 2026, 11:00 ET Siemens partners with Databricks and FFT to turn production data into scalable AI-driven insights

end-to-end set of products, solutions and services to integrate and digitalize the entire value chain. Optimized for the specific needs of each industry, DI's unique portfolio supports customers to achieve greater productivity and flexibility. DI is constantly adding innovations to its portfolio to integrate

More news about: Siemens AG


Jun 11, 2026, 16:32 ET Destinations International Strengthens Global Advocacy Commitment Through Expanded Leadership and Strategic Focus

role, Glenn will help lead the implementation of DI's advocacy strategy, supporting members through policy research, coalition-building initiatives, advocacy tools and destination-focused resources.The expanded advocacy structure directly supports DI's Advocacy & Action Strategic Roadmap,

More news about: Destinations International


Jun 11, 2026, 01:44 ET DKSH Enters Strategic Distribution Partnership with BridgeBio to Support Regulatory Evaluation and Potential Patient Access to Transthyretin Stabilizer for ATTR-CM in Selected Asia Pacific Markets

Last accessed March 2026.  2 Lane T, et al. Circulation. 2019;140(1):16-26.3 Rintell D, et al. Orphanet J Rare Dis. 2021;16(1):70.4 Nativi-Nicolau J, et al. ESC Heart Fail. 2021;8(5):3875-3884About DKSHFor more than 160 years, DKSH

More news about: DKSH Management Ltd.


Jun 09, 2026, 09:00 ET Estudo que acaba de ser publicado, no maior congresso de reumatologia da Europa, demonstra eficácia superior de nova molécula no tratamento da artrite psoriásica já na 16ª semana

rating certainty of evidence—assessing indirectness. BMJ 2025; 389:e083865 doi:10.1136/bmj-2024-08386.4.  Ritchlin CT, et al. Ann Rheum Dis. 2023;82(11):1404–14.5.  Queiro R, et al. Arthritis Res Ther. 2022;24(1):1536.  Belinchón I, et al. J Dermatolog Treat. 2022;33(3):1661–97. 

More news about: UCB Biopharma


Jun 08, 2026, 08:00 ET Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at the EAACI 2026 Congress

www.argobiopharma.com.References : Pedro Giavina-Bianchi P, et al. (2011). CLINICS 66(9): 1627–1636.Aygören-Pürsün, E, et al. (2018). Orphanet J Rare Dis 13(1): 73.

More news about: Argo Biopharmaceutical Co., Ltd


Jun 03, 2026, 07:00 ET Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases

Genetic Testing Working Group. Advancing Genetic Testing in Kidney Diseases: Report From a National Kidney Foundation Working Group. Am J Kidney Dis. 2024 Dec;84(6):751-766.

More news about: Ascidian Therapeutics


Jun 03, 2026, 01:29 ET XCMG ayuda a impulsar los estándares internacionales de la industria de grúas

seguro - Parte 2: Grúas móviles, impulsada por China. Su informe permitió que el proyecto avanzara a la fase de Borrador de Norma Internacional (DIS).En representación de la delegación china, los expertos técnicos de XCMG propusieron un nuevo punto de trabajo para la norma ISO 9927-2,

More news about: XCMG Crane


Jun 03, 2026, 01:23 ET Chinesische Normen erobern die Welt: XCMG hilft, die internationalen Standards der Kranindustrie voranzubringen

Mobilkräne, eine von China angeführte Norm. Durch seine Aktualisierung wurde das Projekt in das Stadium des Entwurfs einer internationalen Norm (DIS) überführt.Als Vertreter der chinesischen Delegation schlugen die technischen Experten von XCMG auch ein neues Arbeitsthema für ISO 9927-2,

More news about: XCMG Crane


Jun 03, 2026, 01:15 ET Les normes chinoises s'internationalisent : XCMG contribue à promouvoir les normes internationales dans le secteur des grues

Grues mobiles, une norme développée sous leadership chinois. Sa mise à jour a permis au projet de passer au stade de projet de norme internationale (DIS).Au nom de la délégation chinoise, les experts techniques de XCMG ont également proposé un nouveau projet de travail relatif à la norme ISO

More news about: XCMG Crane


Jun 03, 2026, 00:04 ET Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

accessed: June 20266 Bracalenti M, Iaccarino L, Doria A. Remission and low disease activity in systemic lupus erythematosus. Rare Dis Orphan Drugs J. 2025;4:28.

More news about: Johnson & Johnson


Jun 02, 2026, 05:14 ET Chinese Standards Go Global: XCMG Helps Advance International Crane Industry Standards

12480-2, Cranes — Safe Use — Part 2: Mobile Cranes, a standard led by China. His update moved the project forward to the Draft International Standard (DIS) stage.Representing the Chinese delegation, XCMG's technical experts also proposed a new work item for ISO 9927-2, Cranes — Inspection — Part

More news about: XCMG Crane


Jun 02, 2026, 04:42 ET Chinese Standards Go Global: XCMG Helps Advance International Crane Industry Standards

12480-2, Cranes — Safe Use — Part 2: Mobile Cranes, a standard led by China. His update moved the project forward to the Draft International Standard (DIS) stage.Representing the Chinese delegation, XCMG's technical experts also proposed a new work item for ISO 9927-2, Cranes — Inspection — Part

More news about: XCMG Crane


Jun 01, 2026, 11:11 ET UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members

Cross-Sectional Study. Indian J Dermatol. 2025;70(5):283-286.Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158–64.Date

More news about: UCB


May 29, 2026, 09:00 ET Icelandic Pavilion Presents SOAK: Rituals of Collective Belonging at the 20th International Architecture Exhibition - La Biennale di Venezia

Architects partner Marcos Zotes, the pavilion is a multidisciplinary collaboration between Basalt Architects (Hrólfur Karl Cela, Marcos Zotes, Perla Dís Kristinsdóttir), design studio Gagarin (Kristín Eva Ólafsdóttir, Nils Wiberg), and artist Rán Flygenring.

More news about: Business Iceland


May 28, 2026, 19:10 ET FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study. Ann Rheum Dis. 2025;84(12):1983-1994. 4 Ritchlin CT, et al. Durable Inhibition of Structural Damage Progression and Improvements in Joint Disease

More news about: Johnson & Johnson


May 27, 2026, 07:01 ET ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

QA, Greene M, Gohill S, et al. Adherence to multi-target stool DNA testing for colorectal cancer screening in the United States. Int J Colorectal Dis. 2025;40:16.Greene M, Stieber B, LeMaster JW, et al. Closing the loop in colorectal cancer screening: real-world adherence to follow-up colonoscopy

More news about: Abbott


May 19, 2026, 18:43 ET Huawei, Sektörün Geleceğini Şekillendiren Şebeke Etkileşimli AIDC Stratejisini Açıkladı

elektroniği, şebeke oluşturma, yüksek/düşük gerilim ve AC/DC güç alanlarındaki teknik uzmanlığından yararlanacaktır.Isı İnovasyonu: Çiplerden Dış Mekanlara Kadar Tam Yaşam Döngüsü Boyunca Isı Yönetiminin Güvenilirliğinin Yeniden Şekillendirmesi. Sıvı soğutmanın nihai değeri ekipman soğutmasında

More news about: Huawei Digital Power


May 19, 2026, 15:14 ET BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data

psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811-818.Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545-568.Mease PJ, Gladman DD, Papp KA, et al. Prevalence

More news about: UCB


May 19, 2026, 08:39 ET FastWave Medical Secures Four New International Patents

string of recognitions and clinical progress for FastWave. The company was named one of Fierce Medtech's 2024 "Fierce 15" companies and was selected as MD+DI's 2025 Medtech Company of the Year. Last year, FastWave completed a 30-patient first-in-human study of its L-IVL coronary platform, following an earlier

More news about: FastWave Medical


May 12, 2026, 08:55 ET NYSE Content Update: Disney CEO Josh D'Amaro Rings Bell Ahead of Upfront Event

19th Annual LatAm CEO Conference as part of the festivities.Opening BellThe Walt Disney Company (NYSE: DIS) celebrates the 2026 Disney UpfrontClosing BellAAR Corp (NYSE: AIR) celebrates its 45th anniversary of listing

More news about: New York Stock Exchange


May 08, 2026, 10:00 ET Duno Health launches the Youth & Vitality Daily Supplement

62 (2018) 561–5708,     J Prev Alz Dis 2021;3(8):329-3349,     J. Clin. Invest.

More news about: Duno Health


May 07, 2026, 20:30 ET Chance Pharma Announces NMPA Acceptance of New Drug Application for Investigational Respiratory Drug CXG87

Thoracic Society, Chinese Medical Association. Guidelines for the prevention and management of bronchial asthma (2024 edition)[J]. Chin J Tuberc Respir Dis, 2025, 48(3): 208-248.Group of Respiratory Therapy and Pulmonary Function Test, Society of Respiratory Medicine, Shanghai Medical Association,

More news about: Chance Pharmaceuticals


May 07, 2026, 16:48 ET 450 MHz LTE: Brezilya için Daha Güçlü, Daha Akıllı Şebeke

yeterli bir telekomünikasyon sistemi şarttır. Buna ek olarak, sektörün bir sonraki adımı LTE gibi özel ağların benimsenmesidir. CEMIG ise hem iç hem de dış araştırmalar yürüttükten sonra 450 MHz frekansını seçti. Bu frekans, 3GPP standardına uygundur ve olgun bir uçtan uca ekosistem sunar. Geniş kapsama

More news about: Huawei


May 07, 2026, 05:59 ET Maple Leaf Foods Reports First Quarter 2026 Financial Results

limited to the following:the benefits and impacts of the Spin-Off being realized, including the projected risks, costs, dis-synergies, and tax consequences;compliance by Maple Leaf Foods, Canada Packers and "specified shareholders", as defined in the

More news about: Maple Leaf Foods Inc.


May 06, 2026, 00:00 ET Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia

dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519-530.[4] Liu

More news about: Alebund Pharmaceuticals


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.